The CANTOS Trial: One Important Step for Clinical Cardiology but a Giant Leap for Vascular Biology

Richard A Baylis; Delphine Gomez; Ziad Mallat; Gerard Pasterkamp; Gary K Owens

doi:10.1161/ATVBAHA.117.310097

The CANTOS Trial: One Important Step for Clinical Cardiology but a Giant Leap for Vascular Biology

Arterioscler Thromb Vasc Biol. 2017 Nov;37(11):e174-e177. doi: 10.1161/ATVBAHA.117.310097. Epub 2017 Sep 28.

Authors

Richard A Baylis¹, Delphine Gomez¹, Ziad Mallat¹, Gerard Pasterkamp¹, Gary K Owens²

Affiliations

¹ From the Robert M. Berne Cardiovascular Research Center (R.A.B., G.K.O.), Department of Biochemistry and Molecular Genetics (R.A.B.), and Department of Molecular Physiology and Biological Physics (G.K.O.), University of Virginia, Charlottesville; Pittsburgh Heart, Lung, Blood and Vascular Medicine Institute (D.G.), Division of Cardiology, University of Pittsburgh School of Medicine, PA (D.G.); Division of Cardiovascular Medicine, University of Cambridge, United Kingdom (Z.M.); Institut National de la Santé et de la Recherche Médicale, Paris Cardiovascular Research Center, France (Z.M.); and Laboratory of Clinical Chemistry, University Medical Centre Utrecht, The Netherlands (G.P.).
² From the Robert M. Berne Cardiovascular Research Center (R.A.B., G.K.O.), Department of Biochemistry and Molecular Genetics (R.A.B.), and Department of Molecular Physiology and Biological Physics (G.K.O.), University of Virginia, Charlottesville; Pittsburgh Heart, Lung, Blood and Vascular Medicine Institute (D.G.), Division of Cardiology, University of Pittsburgh School of Medicine, PA (D.G.); Division of Cardiovascular Medicine, University of Cambridge, United Kingdom (Z.M.); Institut National de la Santé et de la Recherche Médicale, Paris Cardiovascular Research Center, France (Z.M.); and Laboratory of Clinical Chemistry, University Medical Centre Utrecht, The Netherlands (G.P.). gko@virginia.edu.

Abstract

The results of the CANTOS trial provide exciting evidence in support of the inflammatory hypothesis of atherosclerosis in humans, and is the first phase III clinical trial to show clinical benefit of a targeted anti-inflammatory therapy. However, the modest overall clinical benefit and safety concerns with increased susceptibility to fatal infections indicate that we need much more work in this critical area.

Keywords: atherosclerosis; coronary artery disease; inflammation; interleukins; translational medical research.

Publication types

Research Support, N.I.H., Extramural
Review

MeSH terms

Anti-Inflammatory Agents / adverse effects
Anti-Inflammatory Agents / therapeutic use*
Antibodies, Monoclonal / adverse effects
Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Humanized
Atherosclerosis / diagnosis
Atherosclerosis / drug therapy*
Atherosclerosis / immunology
Cardiology*
Clinical Trials, Phase III as Topic
Coronary Artery Disease / diagnosis
Coronary Artery Disease / drug therapy*
Coronary Artery Disease / immunology
Humans
Randomized Controlled Trials as Topic
Treatment Outcome

Substances

Anti-Inflammatory Agents
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
canakinumab

Abstract

Publication types

MeSH terms

Substances

Grants and funding